Fig. 6

Impact of NK cell therapy timing on their ability to prevent post-temozolomide relapse of intracranial mesenchymal glioma stem cell xenografts. (A) Experimental design to examine the effects of delay in NK92MI-IR intracranial injection relative to injection of TMZ to trigger tumour cell depopulation in GSC1123 brain xenografts; (B) Kaplan-Mejer symptom-free survival curves at different intervals between TMZ and NK92MI-IR therapies. Statistical analysis comparing groups: TMZ + media vs. TMZ + NK92MI-IR, for both, GSC tumour models, was conducted by curve analysis using the Gehan-Breslow-Wilcoxon test